I want to start off by saying if you’re new here, welcome and thank you. Odds are, you’ve probably been watching my videos for a while, and now with this newsletter, I can connect with you in a way where I won’t be censored. The format for this thing goes as follows:

I write about whatever the fuck

Read my first fifteen to learn about things ranging from our pedophilic politicians to the creation of football and our pedophilic politicians again. Please DM me on TikTok or Instagram if you want a topic covered. 

The Fat Economy

Skinny black guys all over this country are in shambles, with all of them asking the same question: where the fat white bitches at? You see, it wasn’t that long ago when seventy million adults in the US were considered obese (thirty-five million men and thirty-five million women), and another ninety-nine million were considered overweight (fifty-four million men and forty-five million women). Our country only has 258.3 million adults, which means data from five years ago suggest that two-thirds of the country was obese or overweight (no wonder why American life expectancy rates look like my Fidelity portfolio). 

To put this in perspective, in the 1990s, the obesity rate in America was a little over ten percent. Now? It’s over thirty percent. While BMI is obviously a flawed way to assess how in shape a person is (lifting weights can give you enough additional muscle mass to be considered overweight, according to BMI charts), it’s certainly an indicator. 

678,000 Americans die each year from chronic food-related illness (obesity, diabetes, heart disease, and cancer as a result of a poor diet). That toll is higher than all our combat deaths in every war in American history—combined. That’s right: there are more deaths each year from our food than all the combat deaths from the Revolutionary War through the wars in Afghanistan and Iraq. We all know that big corporations like Nestle, General Mills, and others feed us processed poison and lobby Congress to make it okay (that hasn’t been a secret for a long time). Still, the average American’s response to a flawed and corrupt system has been….something else. 

Let’s be honest here: America’s response to corporate greed hasn’t been protesting outside the gates of an executive’s home- people on one side become obsessed with their body image, count their macros, and take all of the joy out of food. They think that because of their discipline, nobody else has an excuse not to look the way they want to. They hardly consider the amount of personal responsibilities the average American working a corporate job actually has (the man or woman struggling to pay their mortgage with a kid in school). 

The other side? It’s even worse. They bitch about capitalism all day while providing influxes of cash to food delivery apps that barely pay their illegal immigrant employees, all under the guise of being too anxious to cook. They listen to Maintenance Phase and try their very hardest to bring fatphobia into the lexicon of normal people who want nothing to do with them. They believe they’re smart because they can only-kind-of-identify corporate propaganda when they see it, but they only do any actual protesting once a year because to protest, you have to march, and these fat, slovenly fucks can’t do that. 

The rest of us? The eighty percent of Americans who don’t have rich enough parents to spend three hours a day in the gym and cook for themselves instead of living in an apartment riddled with Doordash receipts and clothes that smell wretched? We have to live with the consequences of the giant pieces of shit who continue to cut corners by feeding us seed-oil-drenched shit while trying our best not to let retards on both sides of the political aisle bother us too much. Like I said, none of this is new….except the weight loss drugs that have flooded the market over the past year and a half.

The year was 2017, your SoundCloud playlist wasn’t lyrical (but it was catchy), Elen was still bringing Instagram famous four-year-olds to TV screens all across the country, and a Danish pharmaceutical company named Novo Nordisk had just launched their Type Two Diabetes medication, Ozempic. The drug, with an active ingredient known as semaglutide, targets hunger-regulating hormones in the body, and while the FDA does not approve it as a weight-loss medication, almost every user has had the same experience: they’ve lost weight because it hasn’t made them want to eat as much. Even crazier, testimonials from patients have suggested that Ozempic does more than target a user’s brain from the pleasure receptors they get from eating unhealthy, fattening foods; Ozempic users are reporting that while on the drug they lose the craving for other vices like drinking, smoking, and gambling. 

With Ozempic, Novo Nordisk knew they had a winner, but they needed it to be more accessible. Ozempic made its bones as a Diabetes drug (that’s how it was approved in the first place); to really corner the market on weight loss, the company had to come up with a drug that doctors could prescribe without hesitation. That’s where Wegovy comes in. Wegovy, another Novo Nordisk injectable that’s just a larger dosage of Ozempic, was approved in 2021 for patients with significant obesity or with weight-related conditions, like high blood pressure or high cholesterol. Bingo, Motherfucker. At this point in our timeline, Novo Nordisk has the two biggest semaglutide drugs on the market, and word is traveling all through Hollywood that they work wonders. A few videos of girls with silicone breasts raving about their experiences on the drug later, and even your Dad knows what Ozempic does. Do these drugs have adverse side effects? Sure, but any sound-minded person would trade a little diarrhea for a flat stomach any day of the week. 

As of Friday, Novo Dordisk’s market capitalization was roughly $439 billion—more than Pfizer, Lockheed Martin, and Starbucks combined; in September, it overtook LVMH, the French luxury goods firm, as Europe’s biggest company by market capitalization. There’s now a dogfight in the pharmaceutical industry to produce the first semaglutide-based drug in pill form. Novo Nordisk already has a pill version of semaglutide; it’s called Rybelsus, and it was approved for diabetes patients in 2019. New research released recently shows that the majority of users without diabetes in a clinical study lost an average of fifteen percent of their body weight when given a higher dosage of Rybelsus, a similar level to Wegovy. Novo Nordisk is likely to seek approval for Rybelsus as a weight loss drug.

But American big pharma giants aren’t going down without a fight. Eli Lilly has a slightly different injectable called Mounjaro that was approved last May for Type Two Diabetes. They also have an injectable called Zepbound (which got approved today) and a pill in production called orforglipron. Amgen is working on a hormone-targeting drug. Pfizer has two pills in development. Every name is big pharma wants to get in on the semaglutide gold rush. The market for weight loss medications is expected to balloon to $100 billion by 2030. 

As great as it is that a Danish company is helping so many Americans combat obesity, heart disease, ect., I’m worried about American pharma, and you should be, too. It’s not like Novo Nordisk is without any faults. They paid $58.65 million six years ago because they didn’t disclose a potential life-threatening side effect of a prescription Diabetes drug, the ABPI currently suspends them, they raised the price on its rapid-acting insulin Novolog by 628%, and I’m sure there’s more dirt on them than that. 

Here’s the thing, though: compared to the actions of Eli Lilly and Pfizer, Novo Nordisk looks like an altar boy. The company paying a $58.65 million dollar fine was a huge deal to them, like a straight-A-middle-schooler getting a C. For American pharmaceutical companies, accruing a financial penalty worth tens of millions of dollars is just called Tuesday. Since 2000, Pfizer has paid almost eleven billion dollars in damages. In the same time span, Eli Lilly has paid just under three billion. Ten years ago, Amgen paid one of the biggest fines in pharmaceutical history. These companies are run by some of the most repugnant people imaginable, and because of that, sick people will pay. 

American pharmaceutical companies are putting so much effort into getting on the gravy train, that they aren’t producing enough established drugs patients actually need. Thousands of patients are facing delays in getting treatments for cancer and other life-threatening diseases, with drug shortages in the United States close to an all-time high. Generic medications for cancer (that are affordable for poor people) are insanely hard to come by these days. Fifteen crucial drugs—the kind that can render cancers curable—have been out of stock in hospitals for months. Doctors have had to ration their supplies, skimp on dosages, and swap out prescriptions with inferior alternatives. Researchers estimate that the average drug shortage (including the current one) impacts half a million patients. Antibiotics, ADHD medications, and even Tylenol are all in a shortage. The pharmaceutical industry is blaming it on supply chain issues, but it’s obvious to anyone paying attention that the big pharmaceutical companies are spending most of their energy looking for a weight-loss pill because it’s really profitable, rather than figuring out ways for people in chemotherapy to get their drugs at an affordable price. 

The truth about Ozempic is this: Novo Nordisk has put most of their efforts into treating diabetes for decades, and because of their hard work and ability to innovate, they found a way to save the lives of diabetics while also creating a drug that helps people fight obesity. It’s admirable, and it comes from REAL free-market capitalism. Novo Nordisk has happy employees; they make drugs with the purpose of helping diabetics, and they take into account social responsibility (which is why they haven’t paid nearly as much in fines as a company like Pfizer). In Denmark, the company’s success has been a boon for the entire country—helping its gross domestic product expand by 1.7% in the first half of the year. Denmark’s economy would have contracted by 0.3% without the pharmaceutical sector. Novo is the largest taxpayer in the country, and its revenue helps strengthen the Danish krone and keep interest rates low. 

None of this is the case for most American pharmaceutical companies, which have somehow even made healthcare an oligarchy. For Eli Lilly, it’s about the bottom line: how much profit can we make to ensure that our shareholders are happy? Oh great, there’s a weight-loss boom! Drop everything, let’s do whatever we can to tail their success.

This brings me to my other point: there’s an entire economy around insecurity, especially in women, and plenty of powerful people are not happy with Wegovy and Ozempic for disrupting that. Keeping people fat pays for many houses in Sea Isle, Georgia. The S&P Food & Beverage Select Industry Index has declined 12% over the past three months. Shares of Kraft Heinz are down 10% over the same period. Hershey is down 19%, while Coca-Cola and PepsiCo have shed 9% and 12%, respectively. Shares of medical device companies have dropped on studies that show Novo’s drugs reduced the risk of heart attack and kidney failure. Insulet, which makes insulin pumps, is down 49% over the past three months, while Dexcom, which manufactures glucose monitors, has fallen 23%. Zimmer Biomet, which makes knee-replacement products, has decreased about 21%. And if you don’t think Walmart knew what they were doing when they sold their plus-sized women’s clothing brand, you’re out of your mind. 

Now, these weight loss drugs are still unaffordable for a lot of people (they cost ten grand a year), but once insurance starts playing ball, it’s going to be a challenging ride for the companies that have been feeding us poison since women entered the workforce. Right now, Ozempic is covered by insurance if you have diabetes, but in the first half of the year, Novo Nordisk spent nearly $2.9 million on federal lobbying for a range of policy issues, including obesity drug coverage and the Treat and Reduce Obesity Act. If Wegovy gets covered by insurance, the Southeastern portion of the United States will look a lot thinner, and so will soft drink profit margins. Will fast-food companies get severely battered by a customer base that’s not hungry? I believe they will, but as always, time will tell.